Jonathan A. Ledermann

The Lancet Oncology · 2003–2020

A researcher in the Science corpus: 16 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Who trusts Jonathan A. Ledermann overall

  1. C. Lord
  2. S. Lheureux
  3. Hodgkin Lymphoma

Papers from Jonathan A. Ledermann's perspective

Ordered by how strongly the researchers Jonathan A. Ledermann trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Global cancer statistics (Ca)
  2. Integrated Genomic Characterization of Endometrial Carcinoma (Nature)
  3. A clinically applicable molecular-based classification for endometrial cancers (British Journal of Cancer)
  4. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. (The Lancet)
  5. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. (Journal of Clinical Oncology)
  6. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. (Journal of Clinical Oncology)
  7. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (Annals of Oncology)
  8. Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas (Clinical Cancer Research)
  9. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. (The Lancet)
  10. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. (The Lancet)

Their papers